ECO Animal Health Group plc (AIM:EAH)

Market Cap	36.25M
Revenue (ttm)	84.60M
Net Income (ttm)	658.00K
Shares Out	67.76M
EPS (ttm)	0.01
PE Ratio	55.72
Forward PE	30.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,412
Average Volume	59,559
Open	53.90
Previous Close	53.50
Day's Range	52.00 - 53.90
52-Week Range	50.00 - 135.00
Beta	0.03
RSI	40.14
Earnings Date	Jul 10, 2025

About ECO Animal Health Group

ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, lices, and mange in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1972
• Employees: 227
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EAH

Financial Performance

In 2023, ECO Animal Health Group's revenue was 89.42 million, an increase of 4.82% compared to the previous year's 85.31 million. Earnings were 1.05 million, an increase of 3.97%.